A vaccine developed in China appears to be safe and may protect people from the new coronavirus, researchers reported on Friday.
The early-stage trial, published in the Lancet, was conducted by researchers at several laboratories and included 108 participants aged 18 to 60. Those who received a single dose of the vaccine produced certain immune cells, called T cells, within two weeks. Antibodies needed for immunity peaked at 28 days after the inoculation.
“This is promising data, but it’s early data,” said Dr. Dan Barouch, director of vaccine research at Beth Israel Deaconess Medical Center in Boston, who was not involved in